spray, powder, cream, gel or lotion and oral medication as griseofulvin, fluconazole, itraconazole, terbinafine, ketoconazole etc. Topical therapy sometimes are effective but recurrence is more after stopping. 4 There have been many reports on the therapeutic effects of oral terbinafine and itraconazole on tinea pedis. However till now no reports on these drugs have published in Bangladesh. So this study has been designed to evaluate the comparable efficacy of terbinafine and itraconazole in the treatment of tinea pedis.
Patients and Methods
Over a 3 year period from July 2006 to June 2009, 120 patients of tinea pedis aged 20-60 years were studied in the Department of Dermatology & Venereology at Bangabandhu Sheikh Mujib Medical University, Combined Military Hospital and Shaheed Suhrawardy Hospital and 3 Private Chambers, Dhaka, Bangladesh. The cases were taken based on clinical feature and KOH examination. Routine hematological and KOH examination were done at the start of treatment and at 6 week follow up end point. 80 male and 40 female of whom, 40 had papulosquamous type, 38 had intertriginous type, 30 had hyperkeratotic type and 12 had mixed type. The patients were randomly devided into 2 equal groups. Group-A was given terbinafine 250mg/day and itraconazole 200mg/day in group-B for 2 weeks. All patients had given informed written consent. The patients were excluded from the study if they were pregnant, nursing mother, age below 20 and above 60 years, sensitivity to terbinafine and itraconazole, patients who used any other antifungal (topical/systemic) within a week before initiating this treatment, taking medications that could interfere with trial drugs and having serious systemic illness.
Outcome measures were evaluated weekly during treatment and 2 weeks after cessation of therapy and then the patients (those cured) were followed up for 3 years to see the relapse.
Cure means resolution of signs & symptoms and -ve KOH microscopy.
Relapse means reappearance of signs and +ve KOH microscopy.
Demographic data of the patients and clinical findings and clinical response are summarized in table-I to V.
Results 120 patients (80 male and 40 female) of 20-60 years age group were included into this study. Mean age of the patients was 40.28±10.23 (Table-I ). The duration of the disease ranged from less than 3 months to more than 6 months. The mean duration in group-A was 4.21±2.14 and in group-B was 4.83±2.77. Maximum patients (36.66%) in this study were in 3-6 months duration folllwed less than 3 months (35.83%) in table-II. In our study papulosquamous type was more 40 (33.33%) followed by intertrigenous 38 (31.66%). Mixed type was least variant 12 (10%) followed by hyperkeratotic 30 (25%) ( Table III) . The rate of clinical and mycological cure was found in 56 (93.3%) cases in Group A and 52 (86.6%) in group-B at the follow up end point (6 weeks after starting treatment). In total treatment produced cure in 108 (90%) and no cure in 12 (10%) cases. The severity of the clinical signs and symptoms decreased from baseline to treatment end point and to the treatment end point to follow up end point in both group. The tolerability of study medication was rated good in almost all patients. The patients (those cured) were followed up for 3 years to see the relapse. At 1 year, 12.5% had a relapse, at 2 year, 16.07% had relapse and at 3 year, 17.86% had relapse in group-A and in group-B, 17.30%, 21.15%, 23.07% had relapse at 1,2, and 3 year respectively. 
Discussion
Tinea pedis is the most common fungal infection. It may last for a longtime and may come back after treatment. The affected areas are usually itchy, painful or asymptomatic. It ranges from mild to severe. They may persist or recur but they generally respond to treatment. Longterm medication and preventive measures may be needed. There are several forms of tinea pedis such as papulosquamous, hyperkeratotic, intertriginous, vesico-bullous, mixed type etc. 1, 3 In this study, we have taken papulosquamous type, intertriginous type, hyperkeratotic type and mixed type in both the group A and B. Group-A was given terbinafine 250 mg daily and intraconazole 200 mg 77 daily in group-B for 2 weeks. Terbinafine is a synthetic allaylamine, inhibits ergosterol synthesis by inhibiting squalene epoxidase. It is known that accumulation has a biocidal effect on dermatophyte. In short, terbinafine has both mycostatical and biocidal effects on dermatophyte in general. The effectiveness of itraconazole can be attributed to its high tissue affinity and persistence in the stratum corneum for upto 4 weeks after discontinuation of therapy. 2 In the present study total 120 patients were involved. Male 80 (66.66%) were predominant in the study than female 40 (33.33%) which is consistent with other study done by Lachapelle JM et al. 4 The age of the study population ranged from 20-60 years and maximum patients in our study were in 41-50 years age group 53 (44.16%) followed by 31-40 years age group 30 (25%) which is differing from other study done by Wishart J.M. 5 In this study, the duration of the disease were less than 3 months to more than 6 months, we found maximum number of patients were 3-6 months duration 44 (36.66%) followed by less than 3 months duration 43 (35.83%). This findings also is differing from other study done by Gupta A K et al. 6 In this study, most common clinical varients was found papulosquamous 40 (33.33%) followed by intertriginous 38 (31.66%) which is also differing from other study, where they found intertriginous type was most commonly found. 7 Two groups of people were studied: guoup-A with terbenafine 250 mg daily and group-B with itraconazole 200 mg daily for 14 days. We evaluated weekly during treatment and 2 weeks after cessation of therapy. The clinical response was rated as cure 108 (90%) and no cure 12 (10% R. Savin. 18 treated tinea pedis with 125mg of terbinafine twice daily for 6 weeks and found 88% improvement after 2 weeks follow up period.
Tausch I et al. 19 studied with a course of itraconazole 200mg twice daily for 07 days and terbinafine 250mg daily for 14 days in tinea pedis and revealed clinical improvement 80% in terbinafine group and 79% intraconazole group after follow up period of 6 weeks end point. So in comparing the other studies with our study revealed some of the studies are almost consistent with our result and some of the studies are slightly differing from our study.
The issue of recurrence versus reinfection must always be considered in patients with relapse. Our findings of 12.5% had relapse at 1 year, 16.07% at 2 year and 17.86% at 3 year in group A and in group B at 1 year, 2 year and 3 year had relapse 17.30%, 21.15% and 23.07% respectively suggest that reinfection is more likely than recurrence.
